ArticleAntibiotics (Basel, Switzerland)2020
In Vitro Antimicrobial Activity of Various Cefoperazone/Sulbactam Products.
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Clinical implications of cefoperazone-sulbactam MIC values inJAC-antimicrobial resistance · 2026Article
- Deep learning-driven QSAR and micro-scale MD simulation-guided strategy reveals non-toxic human HGFR inhibitors.Molecular diversity · 2026Article
- Effects of a high proportion of cefoperazone/tazobactam on lung function and bacterial clearance rate in patients with chronic obstructive pulmonary disease and lower respiratory tract infection Klebsiella pneumoniae.European journal of medical research · 2026Article
- Effectiveness and Safety of High-Dose versus Standard-Dose Cefoperazone-Sulbactam in Severe Infections: A Multicenter Retrospective Study.Infection and drug resistance · 2025Article
- A Comparison of in-vitro Pharmacokinetics and Pharmacodynamics of Branded and Its Locally Produced Cefuroxime Sodium AgainstDrug design, development and therapy · 2025Article
- Analysis of anti-infective therapy in a challenging case of brainstem hemorrhage complicated with pneumonia.Heliyon · 2024Article
- Evaluating theIranian journal of microbiology · 2024Article
- Article
- Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease.Antibiotics (Basel, Switzerland) · 2022Article
- Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.Antibiotics (Basel, Switzerland) · 2022Article
- Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.Frontiers in pharmacology · 2022Article
- Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.Infection and drug resistance · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.